Clinical trial
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria
NCT00280215 · Mayo Clinic, Other · Withdrawn
Key facts
| NCT number | NCT00280215 |
|---|---|
| Title | Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria |
| Official title | Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Withdrawn |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hyperoxaluria |
| Intervention type | Drug |
| Interventions | ACEI / Angiotensin converting enzyme inhibitor, ARB /Angiotensin Receptor Blocker, Placebo |
| Enrollment | 0 |
| Start date | Dec 1, 2007 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2011 |
| First posted | Jan 20, 2006 |
| Last update posted | Apr 7, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: